WO2010067980A3 - Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells - Google Patents

Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells Download PDF

Info

Publication number
WO2010067980A3
WO2010067980A3 PCT/KR2009/007162 KR2009007162W WO2010067980A3 WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3 KR 2009007162 W KR2009007162 W KR 2009007162W WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
proviruses
inhibitor
infected cells
latently
Prior art date
Application number
PCT/KR2009/007162
Other languages
French (fr)
Korean (ko)
Other versions
WO2010067980A2 (en
Inventor
홍기종
최병선
김성순
이학성
노성구
현영란
Original Assignee
대한민국(관리부서 질병관리본부장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(관리부서 질병관리본부장) filed Critical 대한민국(관리부서 질병관리본부장)
Priority to KR1020117012184A priority Critical patent/KR101388596B1/en
Publication of WO2010067980A2 publication Critical patent/WO2010067980A2/en
Publication of WO2010067980A3 publication Critical patent/WO2010067980A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a histone deacetylase (HDAC) inhibitor represented by chemical formula 1 that enables reactivation of HIV-1 proviruses from latently HIV-infected cells, and a method for reactivating HIV-1 provirus from latently HIV-infected cells using the inhibitor. The HDAC inhibitor exhibits low cytotoxicity and high stability, and thus can effectively reactivate latent HIV-1 proviruses from a CD4+ T cell reservoir. Accordingly, the HDAC inhibitor is processed together with an HAART cocktail therapeutic drug such as a reverse transcriptase inhibitor AZT, thereby efficiently reducing or removing the latent HIV reservoir.
PCT/KR2009/007162 2008-12-11 2009-12-02 Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells WO2010067980A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020117012184A KR101388596B1 (en) 2008-12-11 2009-12-02 Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12190108P 2008-12-11 2008-12-11
US61/121,901 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010067980A2 WO2010067980A2 (en) 2010-06-17
WO2010067980A3 true WO2010067980A3 (en) 2010-09-23

Family

ID=42243170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007162 WO2010067980A2 (en) 2008-12-11 2009-12-02 Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells

Country Status (2)

Country Link
KR (1) KR101388596B1 (en)
WO (1) WO2010067980A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105597090B (en) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 Reagent for improving survival rate and activity of CD4 positive T lymphocytes and application thereof
KR101978364B1 (en) 2017-06-15 2019-05-14 크리스탈지노믹스(주) Pharmaceutically acceptable salts of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or derivatives thereof and preparing method thereof
US11311603B2 (en) 2018-06-19 2022-04-26 Nantcell, Inc. HIV treatment compositions and methods
JP2022504055A (en) * 2018-10-29 2022-01-13 クリスタルジェノミクス・インコーポレイテッド A pharmaceutical composition containing alkylcarbamoylnaphthaleneyloxyoctenoylhydroxyamide phosphate, tartrate or a combination thereof, and a method for producing the same.
KR20220118747A (en) * 2021-02-19 2022-08-26 크리스탈지노믹스(주) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARS-CoV-2 INFECTIOUS DISEASE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2007052938A1 (en) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof
WO2008068170A1 (en) * 2006-12-04 2008-06-12 William Paul Jackson Hdac inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2007052938A1 (en) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof
WO2008068170A1 (en) * 2006-12-04 2008-06-12 William Paul Jackson Hdac inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YLISASTIGUI, LOYDA ET AL.: "Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression", AIDS, vol. 18, no. ISSUE, 21 May 2004 (2004-05-21), pages 1101 - 1108 *

Also Published As

Publication number Publication date
WO2010067980A2 (en) 2010-06-17
KR20110096028A (en) 2011-08-26
KR101388596B1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
WO2010067980A3 (en) Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells
RU2008139905A (en) PHARMACEUTICAL COMPOSITION FOR EXTERNAL USE
EA201390794A1 (en) BICYCLIC COMPOUND
EP1564210A4 (en) 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2012051492A3 (en) Compounds and methods for inhibiting hiv latency
EA201170960A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIPIN AND LOZARTAN
EA200801144A1 (en) POLYCYCLIC CARBAMOYLPYRIDON DERIVATIVE, HAS INHIBITOR ACTIVITY WITH RESPECT TO HIV INTEGRASES
EA201891103A1 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201200938A1 (en) IMIDAZOPIRIDINE DERIVATIVES AS JAK INHIBITORS
EA201201677A1 (en) DERIVATIVES OF HETEROARILIMIDAZOLONE AS JAK INHIBITORS
MA51204B1 (en) Pharmaceutical forms comprising a plasma kallikrein inhibitor
IL180495A (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
EA201290632A1 (en) DERIVATIVES OF BETULINA
EA200500322A1 (en) COMPOUNDS OF DIHYDROPYRAZOLOPIRIDINE
EA201270216A1 (en) PHARMACEUTICAL COMPOSITION
EA201070635A1 (en) COMPOUNDS INHIBITING DIPEPTIDYLPEPTIDASE-IV, METHODS OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE AGENT
EA201101397A1 (en) Inhibitors of Human Immunodeficiency Virus Replication
NO20084547L (en) Process for Preparation of HIV Protease Inhibitors
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
AR124688A2 (en) A PYRIMIDINE SULFONAMIDE OR A TAUTOMER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EA201190320A1 (en) HETEROCYCLIC SULPHONAMIDES, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS
EA201490222A1 (en) COMBINED COMPOSITIONS BASED ON DARUNAVIR

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20117012184

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2